CDKN2A and head and neck squamous cell carcinoma: We conducted whole exome sequencing (WES) and RNA sequencing (RNA‐seq) in 30 in‐house HNSCC PDCs (patient derived cell lines)[20] to screen for causal mutations/deletions/amplifications in CDKN2A and/or CCND1 and score cell cycle gene signature (Figure1a).